Innovations in conservative endometriosis treatment: An updated review

Minerva Ginecologica

Volumn 63, Issue 3, 2011, Pages 247-249

  Ruhland, B ^a   Agic, A ^a   Krampe, J ^a   Diedrich, K ^a   Hornung, D ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

Drug therapy; Endometriosis; Hormones

Indexed keywords

ANDROGEN; AROMATASE; AROMATASE P450; ASOPRISNIL; BUSERELIN ACETATE; CYCLOOXYGENASE 2 INHIBITOR; CYPROTERONE ACETATE; DANAZOL; DESOGESTREL; DIENOGEST; DROSPIRENONE; DYDROGESTERONE; ETHINYLESTRADIOL; GESTAGEN; GESTODENE; GESTRINONE; GONADORELIN AGONIST; HORMONE RECEPTOR; LEUPRORELIN; LEVONORGESTREL; LYNESTRENOL; MEDROXYPROGESTERONE ACETATE; MEGESTROL ACETATE; MIFEPRISTONE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; NORETHISTERONE ACETATE; ORAL CONTRACEPTIVE AGENT; PLACEBO; SELECTIVE PROGESTOGEN RECEPTOR MODULATOR; UNCLASSIFIED DRUG;

ACNE; AMENORRHEA; ANDROGEN BLOOD LEVEL; ANGIOGENESIS; ATROPHY; BONE DENSITY; BREAST ATROPHY; CONSERVATIVE TREATMENT; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESEARCH; EDEMA; EMOTIONAL DISORDER; ENDOMETRIOSIS; ESTROGEN BLOOD LEVEL; FATIGUE; GENITAL ORGAN ATROPHY; HIRSUTISM; HORMONAL THERAPY; HOT FLUSH; HUMAN; IMMUNOMODULATION; LIBIDO DISORDER; NAUSEA; NONHUMAN; RECOMMENDED DRUG DOSE; RECURRENT DISEASE; REVIEW; SEBORRHEA; SIDE EFFECT; TREATMENT CONTRAINDICATION; TREATMENT DURATION; VAGINAL DRYNESS; WEIGHT GAIN;

ENDOMETRIOSIS; FEMALE; FORECASTING; HORMONES; HUMANS;

EID: 79960978525     PISSN: 00264784     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (108)

1. Eskenazi B, Warner ML. Epidemiology of endometriosis. Obstet Gynecol Clin North Am 1997;24:235-58.
2. Cramer DW, Missmer SA. The epidemiology of endometriosis. Ann NY Acad Sec 2002;955:11-22;discussion 34-6: 396-406.
3. Houston DE, Noller KL, Melton LJ, Selwyn BJ. The epidemiology of pelvic endometriosis. Clin Obstet Gynecol 1988;31:787-800.
4. Sensky TE, Liu DT. Endometriosis: associations with menorrhagia, infertility and oral contraceptives. Int J Gynaecol Obstet 1980;17:573-6.
5. Marques A, Bahamondes L, Aldrighi JM, Petta CA. Quality of life in Brazilian women with endometriosis assessed through a medical outcome questionnaire. J Reprod Med 2004;49:115-20.
6. The American College of Obstetricians and Gynecologist. Medical management of endometriosis: number 11, december 1999. Int J Gynaecol Obstet 2000;71:183-96.
7. Practice Commitee of the American Society for reproductive medicine: Endometriosis and infertility. Fertil Steril 2006;86:S156-60.
8. Kennedy S, Bergqvist A, Chapron C, D'Hooghe T, Dunselman G, Greb RC et al. ESHRE Special Interest Group for endometriosis and endometrium Guideline Development Group. ESHRE Guideline for the diagnosis and treatment of endometriosis. Hum Reprod 2005;20:2698-704.
9. Kuohung W, Jones GL, Vitonis AF, Cramer DW, Kennedy SH, Thomas D et al. Characteristics of patients with endometriosis in the United States and the United Kingdom. Fertil Steril 2002;78:767-72.
10. Candiani GB, Fedele L, Vercellini P, Bianchi S, DiNola G. Repetitive conservative surgery for recurrence of endometriosis. Obstet Gynecol 1991;77:421-4.
11. Vercellini P, Fedele L, Aimi G, De Giorgi O, Consonni D, Crosignani PG. Reproductive performance, pain recurrence and disease relapse after conservative surgical treatment for endometriosis:the predicitive value of the current system. Hum Reprod 2006;21:2679-85.
12. Vercellini P, Fedele L, Pietropaolo G, Frontino G, Somigliana E, Crosignani PG. Progestogens for endometriosis: forward to the past. Hum Reprod Up 2003;9:387-96.
13. Waller KG and Shaw RW. Gonadotropin-releasing hormone analogues for the treatment of endometriosis: long-term follow-up. Fertil Steril 1993;59:511-5.
14. Agic A, Xu H, Finas D, Banz C, Diedrich K, Hornung D. Is endometriosis associated with systemic subclinical inflammation? Gynecol Obstet Invest 2006;62(3):139-47.
15. Ferrero S, Gillott DJ, Remorgida V, Anserini P, Ragni N, Grudzinskas JG. GnRH analogue remarkably down-regulates inflammatory proteins in peritoneal fluid proteome of women with endometriosis. J Reprod Med 2009;54:223-31.
16. Efstathiou JA, Sampson DA, Levine Z, Rohan RM, Zurakowski D, Folkman J et al. Nonsteroidal antiinflammatory drugs differentially suppress endometriosis in a murine model. Fertil Steril. 2005;83:171-81.
17. Allen C, Hopewell S, Prentice A. Non-steroidal anti-inflammatory drugs for pain in women with endometriosis. Cochrane Database Syst Rev 2005;19(4):CD004753.
18. WHO'S pain ladder [Internet]. © Copyright World Health Organization (WHO), 2011 [Internet]. Available from http://www.who.int/cancer/palliative/ painladder/en/ [cited 2011, May 10].
19. Bouquet de Jolinière J, Validire P, Canis M, Doussau M, Levardon M, Gogusev J. Human endometriosis-derived permanent cell line (FbEM-1): establishment and characterization. Hum Reprod Update 1997;3:117-23.
20. Telimaa S, Puolakka J, Ronnberg L, Kauppila A. Placebo-controlled comparison of danazol and high-dose medroxyprogesterone acetate in the treatment of endometriosis after conservative surgery. Gynecol Endocrinol 1987;1:13-23.
21. Dlugi AM, Miller JD, Knittle J. Lupron depot (leuprolide acetate) for depot suspension in the treatment of endometriosis:a randomized, placebo-controlled, double-blind study. Fertil Steril 1990;54:419-27.
22. Fedele L, Bianchi S, Bocciolone L, Di Nola G, Franchi D. Buserelin acetate in the treatment of pelvic pain associated with minimal and mild endometriosis: a controlled study. Fertil Steril 1993;59:516-21.
23. Bergqvist A, Bergh T, Hogström L, Mattsson S, Nordenskjöld F, Rasmussen C. Effects of triptorelin versus placebo on the symptoms of endometriosis. Fertil Steril 1998 69:702-8.
24. Vercellini P, Somigliana E, Viganò P, Abbiati A, Daguati R, Crosignani PG. Endometriosis: current and future medical therapies. Best Pract Res Clin Obstet Gynecol 2008;22:275-306.
25. Bergqvist A, Theorell T. Changes in quality of life after hormonal treatment of endometriosis. Acta Obstet Gynecol Scand 2001;80:628-37.
26. Davis L, Kennedy S, Moore J, Prentice A. Modern combined oral contraceptives for pain associated with endometriosis. Cochrane Database Syst Rev 2007;3:CD001019.
27. Prentice A, Deary AJ, Goldbeck-Wood S, Farquhar C, Smith SK. Gonadotrophin-releasing hormone analogues for pain associated with endometriosis. Cochrane Database Syst Rev 2007;3:CD000346.
28. Wellbery C. Diagnosis and treatment of endometriosis. Am Fam Physician 1999;60:1753-68.
29. Dmowski WP, Cohen MR. Antigonadotropin (danazol) in the treatment of endometriosis. Evaluation of posttreatment fertility and three-year follow-up data. Am J Obstet Gynecol 1978;130:41-8.
30. Telimaa S, Puolakka J, Rönnberg L, Kauppila A. Placebo-controlled comparison of danazol and high-dose medroxyprogesterone acetate in the treatment of endometriosis. Gynecol Endocrinol 1987;1:13-23.
31. Fraser IS, Shearman RP, Jansen RPS, Sutherland PD. A comparative treatment trial of endometriosis using the gonadotrophin-releasing hormone agonist, nafarelin, and the synthetic steroid, danazol. Aust N Z J Obstet Gynaecol 1991;31:158-63.
32. Crosignani PG, Gastaldi A, Lombardi PL, Montemagno U, Vignali M, Serra GB. Leuprorelin acetate depot vs danazol in the treatment of endometriosis: results of an open multicentre trial. Clin Ther 1992;14:29-36.
33. The Australian/New Zealand ZOLADEX Study Group. Goserelin depot versus danazol in the treatment of endometriosis. The Australian/New Zealand experience. Aust N Z J Obstet Gynaecol 1996;36:55-60.
34. Crosigniani P, Olive D, Bergqvist A, Luciano A. Advances in the management of endometriosis:an update for clinicians. Hum Reprod Update 2006;12:179-89.
35. Cobellis L, Razzi S, Fava A, Severi FM, Igarashi M, Petraglia F. A danazol-loaded intrauterine device decreases dysmenorrhea, pelvic pain, and dyspareunia associated with endometriosis. Fertil Steril 2004;82:239-40.
36. Razzi S, Luisi S, Calonaci F, Altomare A, Bocchi C, Petraglia F. Efficacy of vaginal danazol treatment in women with recurrent deeply infiltrating endometriosis. Fertil Steril 2007;88:789-94.
37. Fedele L, Bianchi S, Viezzoli T, Arcaini L, Candiani GB. Gestrinone versus danazol in the treatment of endometriosis. Fertil Steril 1989;51:781-5.
38. Gestrinone Italian Study Group. Gestrinone versus a gonadotropin- releasing hormone agonist for the treatment of pelvic pain associated with endometriosis:a multicenter, randomized, double-blind study. Fertil Steril 1996;66:911-9.
39. Valle RF, Sciarra JJ. Endometriosis: treatment strategies. Ann N Y Acad Sci 2003;997:229-39.
40. Janssens RM, Brus L, Cahill DJ, Huirne JA, Schoemaker J, Lambalk CB. Direct ovarian effects and safety aspects of GnRH agonists and antagonists. Hum Reprod Update 2000;6:505-18.
41. Schweppe KW. Leitlinie für den Einsatz der GnRH-Agonisten zur Behandlung der Endometriose. Zentr Gyn 2005;127:308-13.
42. Batzer FR. GnRH analogs: options for endometriosis-associated pain treatment. J Minim Invasive Gynecol 2006;13:539-45.
43. Child TJ, Tan SL. Endometriosis: aetiology, pathogenesis and treatment. Drugs 2001;61:1735-50.
44. Zupi E, Marconi D, Sbracia M, Zullo F, De Vivo B, Exacustos C. Add-back therapy in the treatment of endometriosis-associated pain. Fertil Steril 2004;82:1303-8.
45. Surrey E, Hornstein M. Prolonged GnRH agonist and add-back therapy for symptomatic endometriosis: long-term follow-up. Obstet Gynecol 2002;99:709-19.
46. Guzick DS, Huang LS, Broadman BA, Nealon M, Hornstein MD. Randomized trial of leuprolide versus continuous oral contraceptives in the treatment of endometriosis-associated pelvic pain. Fertil Steril 2011;95:1568-73.
47. Moore J, Kennedy S, Prentice A. Modern combined oral contraceptives for pain associated with endometriosis (Cochrane Review). Cochrane Database Syst Rev 2000;CD001019.
48. Vercellini P, Somigliana E, Viganò P, Abbiati A, Barbara G, Crosignani PG. Endometriosis: Current therapies and new pharmacological developments. Drugs 2009;69:649-75.
49. Lockhat FB, Emembolu JO, Konje JC. The efficacy, sideeffects and continuation rates in women with symptomatic endometriosis undergoing treatment with an intra-uterine administered progestogen (levonorgestrel): a 3 year follow-up. Hum Reprod 2005;20:789-93.
50. Vercellini P, Aimi G, Panazza S, De Giorgi O, Pesole A, Crosignani PG. A levonorgestrel-releasing intrauterine system for the treatment of dysmenorrhea associated with endometriosis:a pilot study. Fertil Steril 1999;72:505-8.
51. Varma R, Sinha D, Gupta JK. Non-contraceptive uses of levonorgestrel-releasing hormone system (LNG-IUS): a systematic enquiry and overview. Eur J Obstet Gynecol Reprod Biol 2006;125:9-28.
52. Petta CA, Ferriani RA, Abrao MS, Hassan D, Rosa E Silva JC, Podgaec S. Randomized clinical trial of a levonorgestrel releasing intrauterine system and a depot GnRH analogue for the treatment of chronic pelvic pain in women with endometriosis. Hum Reprod 2005;20:1993-8.
53. Vercellini P, Trespidi L, Colombo A, Vendola N, Marchini M, Crosignani PG. A gonadotropin-releasing hormone agonist versus a low-dose oral contraceptive for pelvic pain associated with endometriosis. Fertil Steril 1993;60:75-9.
54. Harada T, Momoeda M, Taketani Y, Hoshiai H, Terakawa N. Low-dose oral contraceptive pill for dysmenorrhea associated with endometriosis: a placebo-controlled, double-blind randomized trial. Fertil Steril 2008;90.1583-8.
55. Johnson N, Farquhar C. Endometriosis. Clin Evid (Online) 2007;2007. pii:0802.
56. Sulak PJ, Cressman BE, Waldrop E, Holleman S, Kuehl TJ. Extending the duration of active oral contraceptive pills to manage hormone withdrawal symptoms. Obstet Gynecol 1997;89:179-83.
57. Sulak P, Thomas J, Ortiz M, Shull BL. Acceptance of altering the standard 21-day/7-day oral contraceptive regimen to delay menses and reduce hormone withdrawal symptoms. Am J Obstet Gynecol 2002;186:1142-9.
58. Coffee AL, Sulak PJ, Kuehl TJ. Long-term assessment of symptomatology and satisfaction of an extended oral contraceptive regimen. Contraception 2007;75:444-9.
59. Seracchioli R, Mabrouk M, Frascà C, Manuzzi L, Savelli L, Venturoli S. Long-term oral contraceptive pills and postoperative pain management after laparoscopic excision of ovarian endometrioma: a randomized controlled trial. Fertil Steril 2010;94:464-71.
60. Muneyyirci-Delale O, Karacan M. Effect of norethindrone acetate in the treatment of symptomatic endometriosis. Int J Fertil Womens Med 1998;43:24-7.
61. The American Fertility Society. Revised American Fertility Society classification of endometriosis: 1985. Fertil Steril 1985;43:351-2.
62. Bergqvist A, Theorell T Changes in quality of life after hormonal treatment of endometriosis. Acta Obstet Gynecol Scand 2001;80:628-37.
63. Riis BJ, Lehmann HJ, Christiansen C. Norethisterone acetate in combination with estrogen: effects on the skeleton and other organs: a review. Am J Obstet Gynecol 2002;187:1101-6.
64. Overton CE, Lindsay PC, Johal B, Collins SA, Siddle NC, Shaw RW. A randomized, double-blind, placebo-controlled study of luteal phase dydrogesterone (Duphaston) in women with minimal to mild endometriosis. Fertil Steril 1994;62:701-7.
65. Schweppe KW. The place of dydrogesterone in the treatment of endometriosis and adenomyosis. Maturitas 2009;65:S23-7.
66. Wong AY, Tang LC, Chin RK. Levonorgestrel-releasing intrauterine system (Mirena) and Depot medroxyprogesterone acetate (Depoprovera) as long-term maintenance therapy for patients with moderate and severe endometriosis:a randomised controlled trial. Aust N Z J Obstet Gynaecol 2010;50:273-9.
67. Vercellini P, Pietropaolo G, De Giorgi O, Pasin R, Chiodini A, Crosignani PG. Treatment of symptomatic rectovaginal endometriosis with an estrogen-progestogen combination versus low-dose norethindrone acetate. Fertil Steril 2005;84:1375-87.
68. Vercellini P, De Giorgio O, Mosconi P, Stellato G, Vicentini S, Crosigniani PG. Cyproterone acetate versus a continous monophasic oral contraceptive in the treatment of recurrent pelvic pain after conservative surgery for symptomatic endometriosis. Fertil Steril 2002;77:52-61.
69. ESHRE Capri Workshop Group. Ovarian and endometrial function during hormonal contraception. Hum Reprod 2001;16:1527-35.
70. Köhler G, Faustmann TA, Gerlinger C, Seitz C, Mueck AO. A dose-ranging study to determine the efficacy and safety of 1, 2, and 4mg of dienogest daily for endometriosis. Int J Gynaecol Obstet 2010;108:21-5.
71. Strowitzki T, Faustmann T, Gerlinger C, Seitz C. Dienogest in the treatment of endometriosis-associated pelvic pain: a 12-week, randomized, double-blind, placebo-controlled study. Eur J Obstet Gynecol Reprod Biol 2010;151:193-8.
72. Strowitzki T, Marr J, Gerlinger C, Faustmann T, Seitz C. Dienogest is as effective as leuprolide acetate in treating the painful symptoms of endometriosis: a 24-week, randomized, multicentre, open-label trial. Hum Reprod 2010;25:633-41.
73. Momoeda M, Harada T, Terakawa N, Aso T, Fukunaga M, Hagino H. Long-term use of dienogest for the treatment of endometriosis. J Obstet Gynaecol Res 2009;35:1069-76.
74. Köhler G, Faustmann TA, Gerlinger C, Seitz C, Mueck AO. A dose ranging study to determine the efficacy and safety of 1, 2 and 4 mg of dienogest daily for endometriosis. Int J Gynaecol Obstet 2010;108:21-5.
75. Harada T, Momoeda M, Taketani Y, Aso T, Fukunaga M, Hagino H. Dienogest is as effective as intranasal buserelin acetate for the relief of pain symptoms associated with endometriosis-a randomized, double-blind, multicenter, controlled trial. Fertil Steril 2009;91:675-81.
76. Vercellini P, Frontino G, De Giorgi O, Aimi G, Zaina B, Crosignani PG. Comparison of a levonorgestrel-releasing intrauterine device versus expectant management after conservative surgery for symptomatic endometriosis: a pilot study. Fertil Steril 2003;80:305-9.
77. Fedele L, Bianchi S, Zanconato G, Portuese A, Raffaelli R. Use of levonorgestrel-releasing intrauterine device in the treatment of rectovaginal endometriosis. Fertil Steril 2001;75:485-8.
78. Bahamondes L, Petta CA, Fernandes A, Monteiro I. Use of the levonorgestrel-releasing intrauterine system in women with endometriosis, chronic pelvic pain and dysmenorrhea. Contraception 2007;75(6 Suppl):S134-9.
79. Speroff L, Darney P. A Clinical Guide for Contraception. Fifth Edition, Philadelphia: Lippincott Williams & Wilkins; 2010.
80. ESHRE Capri Workshop Group. Intrauterine devices and intrauterine systems. Hum Reprod Update 2008;14:197-208.
81. Berlex Pharmaceuticals Mirena Physician Information [Internet]. Available from: http://berlexbayer-health-care.com/html/products/pi/Mirena-PI.pdf. [cited on June 24, 2009].
82. ACOG Committee on Practice Bulletins-Gynecology. ACOG practice bulletin. Clinical management guidelines for obstetrician-gynecologists. Number 59, January 2005. Intrauterine device. Obstet Gynecol 2005;105:223-32.
83. Shulman LP, Nelson AL, Darney PD. Recent developments in hormone delivery system. Am J Obstet Gynecol 2004;190:S39-48.
84. Backman T, Huhtala S, Luoto R, Tuominen J, Rauramo I, Koskenvuo M. Advance information improves user satisfaction with the levonorgestrel intrauterine system. Obstet Gynecol 2002;99:608-13.
85. Crosigniani P, Luciano A, Ray A, Bergqvist A. Subcutaneous depot medroxyprogesterone acetate versus leuprolide acetate in the treatment of endometriosis-associated pain. Hum Reprod 2006;21:248-56.
86. Schlaff WD, Carson SA, Luciano A, Ross D, Bergqvist A. Subcutaneous injection of depot medroxyprogesterone acetate compared with leuprolide acetate in the treatment of endometriosis-associated pain. Fertil Steril 2006;85:314-25.
87. Jain J, Jakimiuk AJ, Bode FR, Ross D, Kaunitz AM. Contraceptive efficacy and safety of DMPA-SC. Contraception 2004;70:269-75.
88. Koide SS. Mifepristone: auxiliary therapeutic use in cancer and related disorders. J Reprod Med 1998;43:551-60.
89. Kettel LM, Murphy AA, Morales AJ, Ulmann A, Baulieu EE, Yen SS. Treatment of endometriosis with the antiprogesterone mifepristone (RU 486). Fertil Steril 1996;65:23-8.
90. Chwalisz K, Perez MC, Demanno D, Winkel C, Schubert G, Elger W. Selective progesterone receptor modulator development and use in the treatment of leiomyomata and endometriosis. Endocr Rev 2005;26:423-38.
91. Altintas D, Kokcu A, Kandemir B, Tosun M, Cetinkaya MB. Comparison of the effects of raloxifene and anastrozole on experimental endometriosis. Eur J Obstet Gynecol Reprod Biol 2010;150.84-7.
92. Riggs BL and Hartmann LC. Selective estrogen-receptor modulators -mechanisms of action and application to clinical practice. N Engl J Med 2003;348:618-29.
93. Stratton P, Sinaii N, Segars J, Koziol D, Wesley R, Zimmer C. Return of chronic pelvic pain from endometriosis after raloxifene treatment: a randomized controlled trial. Obstet Gynecol 2008;111.88-96.
94. Fedele L, Bianchi S, Raffaelli R, Zanconato G. Comparison of transdermal estradiol and tibolone for the treatment of oophorectomized women with deep residual endometriosis. Maturitas 1999;32:189-93.
95. Ailawadi RK, Jobanputra S, Kataria M, Gurates B, Bulun SE. Treatment of endometriosis and chronic pelvic pain with letrozole and norethindrone acetate: a pilot study. Fertil Steril 2004;81:290-6.
96. Simpson ER, Clyne C, Rubin G, Boon WC, Robertson K, Britt K. Aromatase-a brief overview. Annu Rev Physiol 2002;64:93-127.
97. Lake DE, Hudis C. Aromatase inhibitors in breast cancer:an update. Cancer Control 2002;9:490-8.
98. Soysal S, Soysal ME, Ozer S, Gul N, Gezgin T. The effects of post-surgical administration of goserelin plus anastrozole compared to goserelin alone in patients with severe endometriosis: a prospective randomized trial. Hum Reprod 2004;19:160-7.
99. Chishima F, Hayakawa S, Sugita K, Kinukawa N, Aleemuzzaman S, Nemoto N. Increased expression of cyclooxygenase-2 in local lesions of endometriosis patients. Am J Reprod Immunol 2002;48:50-6.
100. Matsuzaki S, Canis M, Pouly JL, Wattiez A, Okamura K, Mage G. Cyclooxygenase-2 expression in deep endometriosis and matched eutopic endometrium. Fertil Steril 2004;82:1309-15.
101. Olivares C, Bilotas M, Buquet R, Borghi M, Sueldo C, Tesone M. Effects of a selective cyclooxygenase-2 inhibitor on endometrial epithelial cells from patients with endometriosis. Hum Reprod 2008;23:2701-8.
102. Cobellis L, Razzi S, De Simone S, Sartini A, Fava A, Danero S et al. The treatment with a COX-2 specific inhibitor is effective in the management of pain related to endometriosis. Eur J Obstet Gynecol Reprod Biol 2004;116:100-2.
103. Yildirim G, Attar R, Ficicioglu C, Karateke A, Ozkan F, Yesildaglar N. Etanercept causes regression of endometriotic implants in a rat model. Arch Gynecol Obstet 2010;12. [Epub ahead of print]
104. Koninckx PR, Craessaerts M, Timmerman D, Cornillie F, Kennedy S. Anti-TNF-alpha treatment for deep endometriosis-associated pain.- a randomized placebo-controlled trial. Hum Reprod 2008;23:2017-23.
105. McLaren J. Vascular endothelial growth factor and endometriotic angiogenesis. Hum Reprod Update 2000;6:45-55.
106. McLaren J, Prentice A, Charnock-Jones DS, Smith SK. Vascular endothelial growth factor (VEGF) concentrations are elevated in peritoneal fluid of women with endometriosis. Hum Reprod 1996;11:220-3.
107. Tan XJ, Lang JH, Liu DY, Shen K, Leng JH, Zhu L. Expression of vascular endothelial growth factor and thrombospondin-1 mRNA in patients with endometriosis. Fertil Steril 2002;78:148-53.
108. Becker CM, Sampson DA, Rupnick MA, Rohan RM, Efstathiou JA, Short SM. Endostatin inhibits the growth of endometriotic lesions but does not affect fertility. Fertil Steril 2005;84:1144-55.